Market Closed -
OTC Markets
20:56:54 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.0122
USD
|
-18.67%
|
|
+11.93%
|
-35.79%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
44.57
|
23.01
|
54.19
|
59.71
|
5.164
|
4.515
|
Enterprise Value (EV)
1 |
50.57
|
29.93
|
60.07
|
66.01
|
10.81
|
10.25
|
P/E ratio
|
-6.36
x
|
-3.51
x
|
-7.09
x
|
-3.55
x
|
-0.69
x
|
-0.48
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
228
x
|
28.8
x
|
-
|
988
x
|
582
x
|
114
x
|
EV / Revenue
|
259
x
|
37.4
x
|
-
|
1,092
x
|
1,218
x
|
259
x
|
EV / EBITDA
|
-10
x
|
-4.6
x
|
-12.2
x
|
-11.2
x
|
-2.56
x
|
-4.41
x
|
EV / FCF
|
-22.6
x
|
-10.3
x
|
-25.6
x
|
129
x
|
22.7
x
|
10.6
x
|
FCF Yield
|
-4.43%
|
-9.73%
|
-3.91%
|
0.78%
|
4.4%
|
9.42%
|
Price to Book
|
-7.35
x
|
-3.5
x
|
34.6
x
|
-25.6
x
|
-1.1
x
|
-0.61
x
|
Nbr of stocks (in thousands)
|
59,433
|
63,035
|
125,197
|
137,904
|
186,442
|
237,649
|
Reference price
2 |
0.7500
|
0.3650
|
0.4328
|
0.4330
|
0.0277
|
0.0190
|
Announcement Date
|
08/04/19
|
14/05/20
|
15/04/21
|
15/04/22
|
17/04/23
|
16/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.1956
|
0.7995
|
-
|
0.0605
|
0.008875
|
0.0395
|
EBITDA
1 |
-5.033
|
-6.502
|
-4.933
|
-5.893
|
-4.227
|
-2.324
|
EBIT
1 |
-5.036
|
-6.506
|
-4.949
|
-8.009
|
-4.653
|
-2.751
|
Operating Margin
|
-2,574.53%
|
-813.73%
|
-
|
-13,246.02%
|
-52,425.6%
|
-6,960.98%
|
Earnings before Tax (EBT)
1 |
-6.755
|
-6.448
|
-6.291
|
-16.02
|
-6.243
|
-8.06
|
Net income
1 |
-6.755
|
-6.448
|
-6.41
|
-16.03
|
-6.243
|
-8.06
|
Net margin
|
-3,453.05%
|
-806.47%
|
-
|
-26,517.21%
|
-70,343.09%
|
-20,394.96%
|
EPS
2 |
-0.1179
|
-0.1041
|
-0.0611
|
-0.1219
|
-0.0400
|
-0.0400
|
Free Cash Flow
1 |
-2.242
|
-2.913
|
-2.346
|
0.5119
|
0.476
|
0.9661
|
FCF margin
|
-1,146.04%
|
-364.33%
|
-
|
846.66%
|
5,362.95%
|
2,444.81%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
08/04/19
|
14/05/20
|
15/04/21
|
15/04/22
|
17/04/23
|
16/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
6
|
6.92
|
5.88
|
6.3
|
5.64
|
5.74
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-1.192
x
|
-1.064
x
|
-1.192
x
|
-1.069
x
|
-1.335
x
|
-2.469
x
|
Free Cash Flow
1 |
-2.24
|
-2.91
|
-2.35
|
0.51
|
0.48
|
0.97
|
ROE (net income / shareholders' equity)
|
109%
|
100%
|
242%
|
4,149%
|
174%
|
129%
|
ROA (Net income/ Total Assets)
|
-147%
|
-215%
|
-47.6%
|
-60.2%
|
-61%
|
-41.3%
|
Assets
1 |
4.594
|
2.998
|
13.48
|
26.65
|
10.24
|
19.53
|
Book Value Per Share
2 |
-0.1000
|
-0.1000
|
0.0100
|
-0.0200
|
-0.0300
|
-0.0300
|
Cash Flow per Share
2 |
0.0300
|
0.0100
|
0
|
0
|
0
|
0
|
Capex
|
-
|
-
|
0.1
|
0.04
|
0.01
|
-
|
Capex / Sales
|
-
|
-
|
-
|
66.98%
|
98.14%
|
-
|
Announcement Date
|
08/04/19
|
14/05/20
|
15/04/21
|
15/04/22
|
17/04/23
|
16/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -35.79% | 4.18M | | +26.28% | 42.68B | | -3.99% | 42.4B | | +45.32% | 40.04B | | -6.20% | 28.31B | | +6.36% | 24.94B | | -21.47% | 18.96B | | +27.58% | 12.3B | | -2.75% | 11.95B | | -2.02% | 11.55B |
Other Biotechnology & Medical Research
|